Healthcare >> Analyst Interviews >> April 5, 2013

Finding Innovation in Biotechnology for Cell Therapy, Oncology and Orphan Drugs

Peaker, Boris
Boris Peaker, Ph.D., is Executive Director and Senior Analyst with Oppenheimer & Co. Inc., covering the biotechnology sector. Prior to joining Oppenheimer & Co. Inc., he was an Analyst at Rodman & Renshaw, covering small and midcap biotech companies across multiple therapeutic areas. Prior to Rodman & Renshaw, Dr. Peaker covered mid- and large-cap U.S.-based biopharmaceutical and biotechnology companies at Cowen Group. He began his career as a Consultant at Keelin Reeds Partners in Palo Alto, California, working exclusively with biotechnology and pharmaceutical companies on asset valuation, R&D portfolio management, M&A strategy, and royalty and equity financing. He holds a Ph.D. in biophysics from Stanford University and a dual B.S. in physics and chemistry from SUNY Stony Brook. Profile
TWST: Last time we spoke, oncology and cell therapy were two areas you were very interested in. Can you give us an update on opportunities in those segments? And, have any other areas